Company: ARWR
Filing Date: 2025-03-07
Form Type: 424B7
Source: 0001193125-25-049889
Chunk: 5

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-03-07
Form: 424B7
Chunk 5
---
 by the Selling Stockholder of the Shares. See “Use of Proceeds” on page S-6 of this prospectus supplement. |

| Risk Factors | You should read the “Risk Factors” section of this prospectus supplement, the accompanying prospectus and in other periodic reports incorporated herein by reference, for a discussion of factors to consider carefully before 
 deciding to invest in our securities.                                                                                                                                                                                          |

| Nasdaq Global Select Market Symbol | “ARWR.” |

S-4

RISK FACTORS

Investing in our securities involves risks. You should carefully consider the risks, uncertainties and other factors described in our most recent Annual
Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K that we have filed or will file with the SEC, and in other documents which are incorporated by reference into this prospectus supplement and the accompanying prospectus before investing in
any of our securities. Our business, financial condition, results of operations, cash flows or prospects could be materially and adversely affected by any of these risks. The risks and uncertainties described in the documents incorporated by
reference herein are not the only risks and uncertainties that you may face.

For more information about our SEC filings, please see “Where You Can Find Additional Information” and “Incorporation of Certain Information by Reference.”

S-5

USE OF PROCEEDS

We will not receive any of the proceeds from the sale of the Shares by the Selling Stockholder.

S-6

SELLING STOCKHOLDER This prospectus supplement covers the possible resale by the Selling Stockholder identified in the table below of up to 11,926,301 Shares. The Selling Stockholder may sell some, all or none of the Shares. We do not know how long the Selling Stockholder will hold the Shares and we currently have no agreements, arrangements or understandings with the Selling Stockholder regarding the sale of any of the Shares. We have entered into the Investor Rights Agreement with the Selling Stockholder pursuant to which, among other things, we have provided them with certain registration rights and agreed to pay certain expenses and indemnify them from certain liabilities in connection with this offering. For more information, see our Annual Report on Form 10-Kfor the year ended September 30, 2024 filed with the SEC on November 26, 2024. The following table presents information regarding the Selling Stockholder and the Shares that they may offer and sell from time to time under this prospectus supplement